Biomedical Engineering Reference
In-Depth Information
[25] FDA. Guidance for Industry on Statistical Approaches to Establishing Bioequivalence, 2001.
Available at http://www.fda.gov/Cder/guidance/3616fnl.htm.
[26] Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to
improve rituximab efficacy. Blood 2004;104:2635-2642.
[27] Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;
232:123-138.
[28] Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D,
Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Immunoglobulin G fragment C
receptor polymorphisms and clinical efficacy of Trastuzumab-based therapy in patients with
HER-2/new-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-1796.
[29] JefferisR. Glycosylationof recombinant antibodytherapeutics. Biotechnol Prog2005;21:11-16.
[30] Huang LH, Li JR, Wroblewski VJ, Beals JM, Riggin RM. In vivo deamidation
characterization of monoclonal antibody by LC/MS/MS. Anal Chem77:2005;1432-1439.
[31] Lindner H, Helliger W. Age-dependent deamidation of asparagine residues in protein. Exp
Gerontol 2001;36 (9):1551-1563.
[32] Tsai PK, Bruner MW, Irwin JI, Yu Ip CC, Oliver CN, Nelson RW, Volkin DB, Middaugh
CR. Origin of the isoelectric heterogeneity of Monoclonal Immunoglobulin h1B4. Pharm
Res 1993;10:1480-1586.
[33] Wang L, Amphlett G, Lambert JM, Blattler W, Zhang W. Structural characterization of a
recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. Pharm
Res 2005;22:1338-1349.
[34] Lyubarskaya Y, Houde D, Woodard J, Murphy D, Mhatre R. Analysis of recombinant
monoclonal antibody isoforms by electrospray ionization mass spectrometry as a strategy for
streamlining characterization of recombinant monoclonal antibody charge heterogeneity.
Anal Biochem 2006;348:24-39.
Search WWH ::




Custom Search